Carl Zeiss Meditec AG (XSWX:AFX) Tariff Resilience Score: 5/10 (As of Jun. 30, 2026)


XSWX:AFX Carl Zeiss Meditec AG XSWX:AFX
80 GF Score
Price CHF25.10
GF Value CHF69.46
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Carl Zeiss Meditec AG Tariff Resilience Score?

Carl Zeiss Meditec AG XSWX:AFX 80 Tariff Resilience Score is 5 as of Jun. 30, 2026. GuruFocus rates XSWX:AFX with a GF Score™ of 80/100 and a GF Value™ of CHF69.46 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 838 Medical Devices & Instruments companies, Carl Zeiss Meditec AG ranks better than 79.12% on this metric.

Carl Zeiss Meditec AG has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Carl Zeiss Meditec AG has Carl Zeiss Meditec AG operates in the global medical technology market, facing moderate tariff exposure. Its diversified manufacturing locations and strong brand provide some resilience against tariff impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Carl Zeiss Meditec AG might have Average Resilient.

Carl Zeiss Meditec AG  (XSWX:AFX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Carl Zeiss Meditec AG Tariff Resilience Score Related Terms

XSWX:AFX vs ISRG, BDX, MDLN: Tariff Resilience Score Comparison

For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Carl Zeiss Meditec AG Tariff Resilience Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Carl Zeiss Meditec AG's Tariff Resilience Score falls into.


XSWX:AFX
80GF Score
Carl Zeiss Meditec AG XSWX:AFX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Carl Zeiss Meditec AG (XSWX:AFX) has a Tariff Resilience Score of 5 as of Jun. 30, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Carl Zeiss Meditec AG ranks #175 out of 838 companies in the Medical Devices & Instruments industry, placing it in the top 20.9%.
Is Carl Zeiss Meditec AG's Tariff Resilience Score too high?
Carl Zeiss Meditec AG's current Tariff Resilience Score is 5. Based on the distribution chart, Carl Zeiss Meditec AG ranks #175 out of 838 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Carl Zeiss Meditec AG has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's Tariff Resilience Score compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Carl Zeiss Meditec AG ranks #175 out of 838 companies for Tariff Resilience Score. This places Carl Zeiss Meditec AG in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Devices & Instruments company?
A good Tariff Resilience Score depends on the Medical Devices & Instruments industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Carl Zeiss Meditec AG's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG (XSWX:AFX) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF69.46, compared to a current price of CHF25.10 — trading 63.9% below its estimated fair value. The current Tariff Resilience Score is 5. Carl Zeiss Meditec AG's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Carl Zeiss Meditec AG (XSWX:AFX), the current Tariff Resilience Score is 5 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carl Zeiss Meditec AG (XSWX:AFX) Overvalued in 2026?

Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued. The current stock price of CHF25.10 is trading 63.9% below its estimated GF Value™ of CHF69.46. GuruFocus considers Carl Zeiss Meditec AG to be Significantly Undervalued.

Key valuation signals for XSWX:AFX:

  • Tariff Resilience Score: 5
  • GF Value™: CHF69.46 vs. price of CHF25.10 (63.9% below fair value)
  • GF Score™: 80/100 with 4 warning signs

No single metric tells the full story. See the XSWX:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Carl Zeiss Meditec AG Business Description

Address Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
80GF Score

Get the complete analysis for XSWX:AFX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF25.10
Price
CHF69.46
GF Value